General Announcement:::- Glenmark receives ANDA approval for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
26-May-2017 12:48:27
Status
New
Announcement Sub Title
:- Glenmark receives ANDA approval for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg
Announcement Reference
SG170526OTHRTUE7
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
26/05/2017 17:00:00
Description (Please provide a detailed description of the event in the box below)
Sub:- Glenmark Pharmaceuticals receives ANDA approval for
Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Attachments

PRUPSING.pdf
Total size =890K